Bronchoalveolar Lavage Lymphocytosis in Hypersensitivity Pneumonitis: A Retrospective Cohort Analysis with Elimination of Incorporation Bias

Meghan Hill

Mayo Clinic

Tananchai Petnak

Mayo Clinic

Teng Moua (✉ moua.teng@mayo.edu)

Mayo Clinic

Research Article

Keywords: hypersensitivity pneumonitis, bronchoalveolar lavage lymphocytosis

Posted Date: August 20th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-825300/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Pulmonary Medicine on February 1st, 2022. See the published version at <https://doi.org/10.1186/s12890-022-01844-z>.

Abstract

Background: Recent studies support the diagnostic role of bronchoalveolar lavage lymphocytosis (BALL) in patients with suspected hypersensitivity pneumonitis (HP). Our study aim was to determine the spectrum of BALL findings with elimination of incorporation bias and assess correlates of positive BALL cut-off and BALL association with long-term outcomes in those with fibrotic disease (f-HP).

Methods: A single-center retrospective cohort study was pursued of patients undergoing diagnostic bronchoscopy for interstitial lung disease. Strict study enrollment was based on recent ATS/JRS/ALAT diagnostic guidance meeting 'moderate' or higher diagnostic confidence. BALL findings were assessed in both fibrotic and non-fibrotic HP patients with regression and survival analysis pursued for correlates of positive BALL cut-off and long-term outcome.

Results: A total of 148 patients (88 fibrotic and 60 non-fibrotic) meeting moderate or higher diagnostic confidence were included. Median BALL in f-HP was 15% compared to 19% in non-fibrotic patients, with only 28% of f-HP meeting diagnostic cut-off ($\geq 30\%$) compared to 41% of non-fibrotic. For f-HP, centrilobular nodules on computed tomography was positively correlated with a diagnostic BALL (OR 4.07; $p = 0.018$) while honeycombing was negatively correlated (OR 6.9×10^{-8} ; $p = 0.001$). Higher BALL was also associated with lower all-cause mortality (HR 0.98; $p = 0.015$).

Conclusion: With elimination of incorporation bias, most patients with well-described HP did not meet diagnostic BALL thresholds. Higher BALL was associated with better long-term survival in those with fibrosis, but its diagnostic role may be more additive than characteristic or distinguishing.

Introduction

Hypersensitivity pneumonitis (HP) is an immune-mediated interstitial lung disease characterized by inhalational antigen exposure leading to a type IV hypersensitivity response and subsequent parenchymal lung injury (1). Bronchoalveolar lavage lymphocytosis (BALL) has been recently proposed to support HP diagnosis(2). A recent diagnostic guideline from the ATS/JRS/ALAT recommends the use of BALL with a lymphocyte count of greater than or equal to 30% as increasing diagnostic confidence (3). Evidence for this recommendation references prior studies demonstrating comparatively higher BAL lymphocyte counts in HP compared to other interstitial lung disease (ILD) (4–9). Two recent systematic reviews and meta-analyses report higher BALL in HP though pooled findings suggested less predictive characteristics(4, 10). The authors highlight several important limitations including the aggregation of older studies with varied diagnostic criteria and incorporation bias, where BALL itself may have been used to make initial diagnoses for study inclusion.

Prognostic significance has also been reported for BALL findings in HP. Higher counts have been associated with improved survival (11, 12) and better response to treatment (13, 14). However, such findings remain unclear in patients with fibrosis as prior clinical categorizations based on suspected duration of symptoms or antigen exposure ('acute', 'subacute', and 'chronic') did not specifically

distinguish between fibrotic or non-fibrotic presentations. It is known that fibrosis is associated with greater mortality in HP(15) at the same time also associated with lower BALL counts compared to non-fibrotic patients(16).

The aims of our study were to determine the extent and frequency of BALL findings in patients with HP diagnosed according to recent international guidance without the inclusion of BALL as a diagnostic criterion and assess clinical correlates of diagnostic BALL findings and its association with survival in those with fibrosis.

Methods

Institutional review board (IRB) approval was obtained (IRB #20–000211). A computer-assisted search was used to identify individuals 18-years or older with ILD and bronchoscopy as diagnostic and procedural search terms completed at Mayo Clinic (Rochester, MN) from January 1, 2005 to December 31, 2019. Individual cases were reviewed by study members and included if other causes of ILD were excluded and criteria were met for ‘definite’ (> 90%), ‘high’ (80–89%), or ‘moderate’ (70–79%) diagnostic confidence levels, according to the recent 2020 ATS/JRS/ALAT diagnostic guideline(3). Most importantly, BALL was not included as a diagnostic criterion to specifically avoid incorporation bias, with patients not meeting at least ‘moderate’ diagnostic confidence without BALL excluded for the purposes of this study.

Additional study variables included age, sex, smoker status, date of clinical diagnosis, histopathologic findings, documented exposure history, HP precipitin serology, chest CT findings, and pulmonary function testing (PFT) (percent predicted total lung capacity (TLC%), forced volume capacity (FVC%), and diffusion capacity for carbon monoxide (DLCO%) according to standard laboratory criteria). Classification of fibrotic vs non-fibrotic HP was defined by the presence of radiologic fibrosis (reticulation or honeycombing) on presenting CT, with individual scans reviewed for ground glass opacities (GGO), mosaic attenuation, and centrilobular nodules. Scans were also assessed by two study members using criteria described in the 2020 ATS/JRS/ALAT guideline for categorization into ‘typical’, ‘compatible’, or ‘indeterminate’ radiologic presentations. Reports of histopathologic findings from diagnostic surgical or transbronchial forceps or cryobiopsies were also reviewed according to guideline criteria and categorized into ‘typical’, ‘compatible’, or ‘indeterminate’ for HP.

Statistical Analysis

Statistical analysis was performed using JMP (Version 14.0, Cary NC). Summary statistics were presented as mean and standard deviation or median and 25–75% interquartile range (IQR) for continuous variables and number and percent for categorical variables. Baseline characteristics of patients with fibrotic and non-fibrotic HP were compared using Wilcoxon rank-sum and χ^2 tests. Presenting case frequencies for various BALL thresholds (10% cut-offs) were collated for fibrotic and non-fibrotic patients. A BALL cut-off $\geq 30\%$ (as proposed by recent international guidance) was used to

stratify positive vs negative findings in both subtypes. Univariable logistic regression was performed to determine clinical and radiologic correlates of elevated BALL ($\geq 30\%$) in patients with fibrotic disease

All patients without reported dates of death in the medical record were reviewed using the United States Social Security Death Index (USSDI). If date of death was not found, date of the last USSDI search minus six months was used as last date of last known alive or follow-up. Survival time was defined in months from the date of initial clinical assessment for ILD to date of death or last known alive, with censoring of live patients. Cox proportional hazards regression was performed in the f-HP group to determine unadjusted and adjusted predictors of all-cause mortality, using a priori selected covariables of age, sex, and presenting FVC% for multivariable analysis. Survival was stratified by radiologic fibrosis at presentation and in the fibrotic subgroup by BALL cut-off $\geq 30\%$, using Kaplan-Meier and Log rank. Two-sided P values < 0.05 were considered statistically significant.

Results

A total of 148 (88 fibrotic and 60 non-fibrotic) of 224 screened patients with suspected HP who underwent bronchoscopy were included in the study (case selection presented in Fig. 1). Baseline clinical characteristics and criteria meeting recent consensus guidance for HP diagnosis are presented in Table 1. Fibrotic patients were slightly older (65 vs 60, $P < 0.0001$) with no differences in sex, smoking history, frequency of solicited exposure or serology findings. Fibrotic patients also had lower pulmonary function findings compared to non-fibrotic. Frequency of positive exposure history and precipitin testing was similar between fibrotic and non-fibrotic patients, dominated by avian antigen. Of note, exposure history was solicited and unknown in 43% of fibrotic patients, compared to 23% of those without fibrosis. Specific radiologic findings including GGO (78%) and mosaic attenuation (65%) were found commonly in patients with f-HP, with centrilobular nodules (17%) and honeycombing (17%) occurring less frequently. Histopathology was dominated by consistent or probable HP findings (83% in fibrotic, 95% in non-fibrotic). Based on combinations of clinical findings, 'moderate' diagnostic confidence levels were reached in the majority of fibrotic and non-fibrotic pts (62% and 58% respectively), followed by 'high' (24% vs 25% respectively) and 'definite' (14% and 17% respectively).

Table 1

) Baseline Characteristics and ATS/ALAS/JRS Diagnostic Findings and Diagnostic Confidence (N = 148)

Characteristic	Fibrotic (N = 88)	Non-fibrotic (N = 60)	P value
Age at dx, years (mean SD (range))	65 (11.6)	60 (13.9)	< 0.0001
Sex, M (%) / F (%)	45 (51)	24 (40)	0.182
Ever smoking history, N (%)	31 (35)	25 (41)	0.429
TLC%, median (IQR 25–75) (N = 105)	69 (60–81)	81 (71–98)	< 0.0001
FVC%, median (IQR 25–75) (N = 130)	61 (52–76)	76 (66–84)	0.0006
DLCO%, median (IQR 25–75) (N = 118)	45 (37–52)	58 (48–72)	< 0.0001
Initial treatment, N (%)	66 (75)	50 (83)	0.159
Corticosteroids	8 (9)	1 (2)	
Steroid-sparing agent	14 (16)	8 (13)	
None/observed			
Short-term clinical course (6–12 months), N (%)	70 (80)	48 (80)	0.829
Improved/stabilized	8 (9)	4 (7)	
Worsened	10 (11)	8 (13)	
Unknown			
All-cause mortality, N (%)	40 (45)	8 (13)	< 0.0001
Exposure hx, N (%)	23 (26)	18 (30)	0.159
Avian	15 (17)	15 (25)	
Mold/bacterial	8 (9)	9 (15)	
Other	4 (5)	4 (7)	
Multiple	38 (43)	14 (23)	
Documented unknown			

Characteristic	Fibrotic (N = 88)	Non-fibrotic (N = 60)	P value
Precipitin testing, N (%)	22 (25)	9 (15)	0.391
Positive avian	6 (7)	3 (5)	
Positive mold/bacterial	6 (7)	3 (5)	
Positive multiple	42 (48)	31 (52)	
Negative	12 (14)	14 (23)	
Not obtained			
Individual radiologic findings			
GGO, N (%)	69 (78)	50 (83)	-
Mosaic attenuation, N (%)	58 (65)	36 (60)	-
Centrilobular nodules, N (%)	15 (17)	18 (30)	-
Reticulation/traction bronchiectasis, N (%)	82 (96)	-	-
Honeycombing, N (%)	15 (17)	-	-
Overall CT pattern for HP, N (%)	52 (59)	32 (53)	0.477
Typical	22 (25)	10 (17)	
Compatible	14 (16)	18 (30)	
Indeterminate			
Histopathology findings, (N = 133)	(N = 72)	(N = 58)	0.125
Consistent, N (%)	42 (51)	40 (69)	
Probable, N (%)	23 (32)	15 (26)	
Indeterminate, N (%)	10 (14)	3 (5)	
Overall ATS/JRS/ALAT Diagnostic Confidence Level	55 (62)	35 (58)	0.844
Moderate, N (%)	21 (24)	15 (25)	
High, N (%)	12 (14)	15 (17)	
Definite, N (%)			

BAL percent differential and lymphocyte findings as stratified by fibrotic and non-fibrotic subgroups are presented in Table 2. Median BALL was 15% (IQR 3–31) in fibrotic patients compared to 19% (IQR 10–47) in non-fibrotic (P = 0.005). Among patients with fibrotic disease, the largest proportion were those with

BALL less than 10% (42%). Only 28% of patients with f-HP had BALL $\geq$ 30% compared to 41% of patients with non-fibrotic disease (P = 0.09).

Table 2
) Bronchoalveolar percent differential and lymphocytosis distribution

Characteristic	Fibrotic (N = 88)	Non-fibrotic (N = 60)	P value
Lymphocyte (%), mean, SD (median, (IQR 25–75))	19, 18 (15 (3–31))	29, 23 (19 (10–47))	0.005
Neutrophil (%), mean, SD (median, (IQR 25–75))	23, 22 (15 (7–33))	19, 19 (15 (4–28))	0.289
Macrophage (%), mean, SD (median, (IQR 25–75))	56, 24 (57 (39–79))	51, 24 (53 (26–71))	0.245
BAL lymphocytosis, N (%)			
<10%, N (%)	37 (42)	13 (22)	-
10–19%, N (%)	19 (22)	20 (33)	-
20–29%, N (%)	7 (8)	2 (3)	-
30–39%, N (%)	8 (9)	5 (8)	-
40–49%, N (%)	6 (7)	7 (12)	-
50–59%, N (%)	7 (8)	3 (5)	-
> 60%, N (%)	4 (5)	10 (17)	-
Total $\geq$ 30%, N (%)	25 (28)	25 (41)	0.09

Table 3 represents univariable correlates of diagnostic BALL ($\geq$ 30%) in patients with f-HP. Presenting clinical findings including demographics (age, sex, and smoking history), exposure history and type, pulmonary function, and serology findings did not appear to correlate with positive BALL. Presence of centrilobular nodules on CT was positively correlated with diagnostic BALL (OR 4.07 (1.28–12.93); P = 0.018), while honeycombing was negatively correlating (OR $6.9 \times e^{-8}$ ($0.107e^{-19}$); P = 0.001).

Table 3

) Univariable clinical predictors of BALL $\geq 30\%$ in patients with fibrotic hypersensitivity pneumonitis (N = 88)

Characteristic	OR (95% CI)	P value
Age*	0.98 (0.94–1.02)	0.392
Male sex	0.74 (0.29–1.91)	0.542
Ever smoker	0.52 (0.18–1.49)	0.210
TLC%*	1.01 (0.97–1.05)	0.467
FVC%*	1.00 (0.98–1.03)	0.763
DLCO%*	1.01 (0.97–1.04)	0.524
Any positive HP serology, (excluding untested, N = 12)	1.01 (0.36–2.83)	0.978
Any identifiable exposure history (excluding those with unknown exposures, N = 38)	1.38 (0.52–3.61)	0.508
Avian	1.58 (0.47–5.65)	0.457
Mold/bacterial	0.96 (0.25–3.38)	0.948
GGO	0.76 (0.26–2.45)	0.638
Mosaic attenuation	1.04 (0.39–2.93)	0.927
Centrilobular nodules	4.07 (1.28–12.93)	0.018
Honeycombing	$6.9 \times e^{-8}$ (0- $1.07e^{-19}$)	0.001
*Unit risk ratios		

Univariable and multivariable Cox regression predictors of all-cause mortality for fibrotic patients are presented in Table 4. Higher BALL as a continuous variable was associated with adjusted and unadjusted lower all-cause mortality (adjusted HR 0.98 (0.96–0.99); $P = 0.015$). A cubic spline representing the relationship between BALL and predicted adjusted hazard ratio in patients with f-HP is presented in Fig. 2. Increased HR was observed with lower BALL counts. A categorical BALL cut-off $\geq 30\%$ was associated with decreased risk of death on univariable analysis (HR 0.431 (0.19–0.95); $P = 0.027$) but not after adjustment for a priori covariables (HR 0.47 (0.21–1.08); $P = 0.058$). The other only independent predictor of mortality was radiologic honeycombing (HR 2.64 (1.15–6.06); $P = 0.022$).

Table 4

) Univariable and multivariable Cox proportional hazards regression analysis of all-cause mortality predictors in f-HP*

Characteristic	HR (95% CI)	P value	HR [¶] (95% CI)	P value
Age*	1.07 (1.02–1.11)	0.0003	1.09 (1.04–1.14)	0.0002
Male sex	1.42 (0.75–2.71)	0.276	-	-
Ever smoker	1.60 (0.83–3.08)	0.165	-	-
Any identifiable exposure history	0.68 (0.35–1.29)	0.241		
TLC%*	0.98 (0.96–1.01)	0.147	-	-
FVC%*	0.99 (0.98–1.02)	0.786	-	-
DLCO%*				
Any positive HP serology (excluding those not done, N = 12)	1.34 (0.68–2.67)	0.398	-	-
BALL %*	0.97 (0.95–0.99)	0.004	0.98 (0.96–0.99)	0.015
BAL lymphocytosis $\geq$ 30%	0.431 (0.19–0.95)	0.027	0.47 (0.21–1.08)	0.058
GGO	0.75 (0.37–1.56)	0.466	-	-
Mosaic attenuation	0.67 (0.36–1.29)	0.238	-	-
Centrilobular nodules	0.27 (0.08–0.89)	0.011	0.31 (0.09–1.02)	0.054
Honeycombing	2.65 (1.23–5.70)	0.012	2.64 (1.15–6.06)	0.022
[¶] Adjusted for a priori covariables of age, sex, and FVC%,				
*Unit risk ratios				

Kaplan-Meier comparison of survival in f-HP as stratified by diagnostic BALL cut-off is presented in Fig. 3. Patients with BALL $\geq$ 30% at presentation had better survival (Log rank 0.034, median survival 262 months versus 79 months). Kaplan-Meier survival between fibrotic and non-fibrotic HP is presented in

Fig. 4. Long-term outcome was worse for fibrotic patients with a median survival of 77 months compared to greater than 200 months (median not reached) in non-fibrotic (Log rank < 0.0001).

Discussion

Prior studies assessing the diagnostic and prognostic utility of BALL in fibrotic and non-fibrotic HP may be limited by varied diagnostic criteria and incorporation bias, hindering broad application to current practice. Our findings are derived from a cohort of well-characterized HP patients meeting at least 'moderate' or higher diagnostic confidence levels according to recent 2020 ATS/JRS/ALAT diagnostic guidance, without the addition of BALL as a diagnostic criterion (3). Using this approach, we found lower frequencies of diagnostic BALL in both fibrotic and non-fibrotic subtypes and higher comparative BALL counts in non-fibrotic vs fibrotic patients. There was also correlation of BALL with long-term survival in those presenting with fibrosis.

Our study confirms BALL counts are lower in fibrotic compared to non-fibrotic HP patients (median BALL 15% vs 19% respectively, $P = 0.005$). Higher BALL counts and increased frequency of positive cut-offs have been previously reported in non-fibrotic patients. Adams et al. reported median BALL of 46% and 19% respectively in 17 non-fibrotic and 60 fibrotic patients undergoing diagnostic bronchoscopy (5). Takei et al applied a recent Delphi consensus statement for f-HP diagnosis to consecutively presenting ILD patients (using a BALL cut-off > 40%) and found only 19% of MDD-diagnosed fibrotic patients had diagnostic BALL findings(17). Frequency of diagnostic BALL was higher at 40% in one study using a lower diagnostic cut-off of 20% (16). Median BALL was only 16% in another study of 160 chronic HP patients (85% with reported fibrosis) diagnosed according to prior criteria proposed by Schuyler and colleagues (11, 18). Caillaud and colleagues reported BALL findings in 139 HP patients from five French centers categorized according to presentations of acute, subacute, or chronic disease duration (6). These BALL findings were much higher with a mean of 42% in those classified as chronic. We again eliminated incorporation bias in our study by reviewing only patients meeting 'moderate' or higher diagnostic confidence levels without the contribution of BALL. With that approach, only 28% of fibrotic and 41% of non-fibrotic patients met current consensus criteria for diagnostic BALL. More so, among patients with fibrotic disease, the largest proportion were those with BALL counts less than 10% (42%), as might be observed in healthy non-smokers (19).

Depending on diagnostic cut-off and study-specific criteria for inclusion, reported frequencies of diagnostic BALL varied significantly but occurred less than 50% of the time in most studies, particularly when BALL was being assessed for diagnostic utility. This lower frequency suggests likely overlap with other ILD, as demonstrated by the findings of two recent meta-analyses(4, 10). Both found lower range sensitivity and specificity for BALL as a diagnostic predictor (depending on cut-off 20% vs 30%), with expected inverse relationship between sensitivity and specificity (higher specificity at the cost of lower sensitivity). This was particularly true among fibrotic patients where the AUC for differentiating f-HP from IPF or sarcoid was reported as poor at 0.54 and 0.44 respectively in one meta-analysis (4). Lower sensitivity and specificity with poor predictive characteristics for distinguishing HP from other ILD,

particularly among fibrotic patients, suggests BALL may be more additive than characteristic or distinguishing, as further supported by our study after specific elimination of incorporation bias.

As such, in patients with suspected f-HP and often more clinically severe disease, predicting procedural yield may be relevant to minimize bronchoscopy-related risk or complications. We assessed pre-procedural parameters in those with fibrosis and found no presenting demographics, exposure type, pulmonary function, or positive precipitin serology correlated with a greater likelihood of diagnostic BALL. Only radiologic findings of centrilobular nodules and honeycombing appeared to support higher and lower likelihoods of diagnostic findings respectively. A similar correlation of BALL findings (using a 20% cut-off) with radiologic honeycombing was reported by De Sadeleer and colleagues(16). Honeycombing was found in 50.9% of those with lower BALL compared to only 13.9% of those with higher BALL. Considering the higher rate of honeycombing in their study compared to ours (36% vs 17%), no patient with honeycombing reached diagnostic BALL in our study.

BALL has also been reported to be predictive of long-term outcomes (13, 14). A study of 160 chronic HP patients found a positive association of higher BALL with improved survival (11). De Sadeleer and colleagues reported improved survival in fibrotic patients stratified by BALL cut-off $>$ or $<$ 20%, with stratification by honeycombing also having similarly poor survival when present. BALL was inversely correlated with honeycombing in their study, with the latter on adjusted Cox regression remaining predictive of poorer outcome while BALL was not. We reviewed univariable and multivariable predictors of all-cause mortality in our fibrotic cohort and found higher BALL at presentation to be independently predictive of survival. As BALL was also inversely colinear with honeycombing in our study, we did not adjust for honeycombing in the Cox regression model, noting again none with honeycombing had a diagnostic BALL in our cohort.

Our study has several limitations. First, its retrospective design can only assume correlation but not causation. We also did not specifically compare BALL findings in HP to other ILD subtypes, focusing on reporting BALL in carefully selected patients meeting updated and strict diagnostic guidance, categorized according to levels of diagnostic confidence. Our primary goal was also to apply this recent diagnostic approach with elimination of incorporation bias to obtain a sense of relevant BALL findings in otherwise diagnosable disease. This methodologic approach naturally selects for patients whose diagnoses were already likely to have been made without BALL and therefore cannot explore the role of BALL in increasing diagnostic confidence in those whose presenting data are inconclusive or missing. However, based on our findings bronchoscopy appears to be unjustified as positive BALL results in otherwise diagnosable disease appears to be low and likely similar or overlapping with other ILD. A majority of patients in our study also underwent biopsy to achieve inclusion criteria of 'moderate' or higher diagnostic confidence levels, suggesting more aggressive assessment was still pursued despite available BALL findings, which may not be typical of real-world practices (as reflected for example in the study by Adams et al (5)). This obtaining of additional biopsy is perhaps the result of lower overall BALL findings overall in our cohort or clinically suspected nonspecific elevation without other supportive criteria.

Conclusion

In a cohort of well-described HP patients meeting ‘moderate’ or greater diagnostic confidence levels without incorporation bias, most fibrotic and non-fibrotic HP patients did not meet a diagnostic BALL threshold of $\geq 30\%$ despite presenting with other typical clinical, radiologic, or histopathologic findings. Only radiologic findings of centrilobular nodules and honeycombing correlated with greater and lower likelihood of diagnostic BALL in those with fibrosis, with higher BALL findings being independently associated with better long-term survival. Based on our findings, BALL appears to be prognostic, but its diagnostic role may be more additive than characteristic or distinguishing in those with fibrotic presentations.

Abbreviations

Bronchoalveolar Lavage BAL

Bronchoalveolar Lavage Lymphocytosis BALL

Hypersensitivity Pneumonitis HP

Fibrotic Hypersensitivity Pneumonitis f-HP

Interstitial Lung Disease ILD

Institutional Review Board IRB

High Resolution Computed Tomography HRCT

Pulmonary Function Testing PFT

Functional Vital Capacity FVC

Ground Glass Opacities GGO

Total Lung Capacity TLC

Diffusion Lung Capacity DLCO

United States Social Security Death Index USSDI

American Thoracic Society ATS

Japanese Respiratory Society JRS

The Latin American Thoracic Association ALAT

Interquartile Range IQR

Declarations

Ethics approval and consent to participate

Study was approved by Mayo Clinic Institutional Review Board prior to study initiation.

Consent for publication

None

Availability of data and materials

The datasets generated and/or analyzed during the current study are not publicly available due institutional review board limitation but are available from the corresponding author on reasonable request.

Competing interests

All authors report no related disclosures or conflicts of interest.

Funding

None

Authors' contributions

All authors contributed equally to the completion of this work.

References

1. Vasakova M, Morell F, Walsh S, Leslie K, Raghu G. Hypersensitivity Pneumonitis: Perspectives in Diagnosis and Management. *Am J Respir Crit Care Med*. 2017;196(6):680-9.
2. Bonella F, Costabel U. The perpetual enigma of bronchoalveolar lavage fluid lymphocytosis in chronic hypersensitivity pneumonitis: is it of diagnostic value? *Eur Respir J*. 2020;56(2).
3. Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, et al. Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2020;202(3):e36-e69.
4. Patolia S, Tamae Kakazu M, Chami HA, Chua A, Diaz-Mendoza J, Duggal A, et al. Bronchoalveolar Lavage Lymphocytes in the Diagnosis of Hypersensitivity Pneumonitis among Patients with Interstitial Lung Disease. *Ann Am Thorac Soc*. 2020;17(11):1455-67.

5. Adams TN, Newton CA, Batra K, Abu-Hijleh M, Barbera T, Torrealba J, et al. Utility of Bronchoalveolar Lavage and Transbronchial Biopsy in Patients with Hypersensitivity Pneumonitis. *Lung*. 2018;196(5):617-22.
6. Caillaud DM, Vergnon JM, Madroszyk A, Melloni BM, Murris M, Dalphin JC, et al. Bronchoalveolar lavage in hypersensitivity pneumonitis: a series of 139 patients. *Inflamm Allergy Drug Targets*. 2012;11(1):15-9.
7. Godard P, Clot J, Jonquet O, Bousquet J, Michel FB. Lymphocyte subpopulations in bronchoalveolar lavages of patients with sarcoidosis and hypersensitivity pneumonitis. *Chest*. 1981;80(4):447-52.
8. D'Ippolito R, Chetta A, Foresi A, Marangio E, Castagnaro A, Merliniaft S, et al. Induced sputum and bronchoalveolar lavage from patients with hypersensitivity pneumonitis. *Respir Med*. 2004;98(10):977-83.
9. Costabel U, Bross KJ, Marxen J, Matthys H. T-Lymphocytosis in Bronchoalveolar Lavage Fluid of Hypersensitivity Pneumonitis - Changes in Profile of T-Cell Subsets during the Course of Disease. *Chest*. 1984;85(4):514-8.
10. Adderley N, Humphreys CJ, Barnes H, Ley B, Premji ZA, Johansson KA. Bronchoalveolar Lavage Fluid Lymphocytosis in Chronic Hypersensitivity Pneumonitis: A Systematic Review and Meta-Analysis. *Eur Respir J*. 2020.
11. Ojanguren I, Morell F, Ramon MA, Villar A, Romero C, Cruz MJ, et al. Long-term outcomes in chronic hypersensitivity pneumonitis. *Allergy*. 2019;74(5):944-52.
12. Walscher J, Gross B, Bruhwylter J, Morisset J, Heussel CP, Lasitschka F, et al. Prognostic impact of bronchoalveolar lavage lymphocytosis in patients with chronic Hypersensitivity Pneumonitis. *Eur Respir J*. 2018;52.
13. De Sadeleer L, Hermans F, De Dycker E, Yserbyt J, Verschakelen JA, Verbeken EK, et al. Impact of BAL lymphocytosis and honeycombing presence on corticosteroid treatment effect in Fibrotic Hypersensitivity Pneumonitis. *Eur Respir J*. 2019;54.
14. Raimundo S, Melo N, Mota P, Guimaraes S, Moura CS, Cunha R, et al. Factors predicting response to azathioprine in chronic hypersensitivity pneumonitis - the importance of BAL lymphocytosis. *Eur Respir J*. 2018;52.
15. Fernandez Perez ER, Kong AM, Raimundo K, Koelsch TL, Kulkarni R, Cole AL. Epidemiology of Hypersensitivity Pneumonitis among an Insured Population in the United States: A Claims-based Cohort Analysis. *Ann Am Thorac Soc*. 2018;15(4):460-9.
16. De Sadeleer LJ, Hermans F, De Dycker E, Yserbyt J, Verschakelen JA, Verbeken EK, et al. Impact of BAL lymphocytosis and presence of honeycombing on corticosteroid treatment effect in fibrotic hypersensitivity pneumonitis: a retrospective cohort study. *Eur Respir J*. 2020;55(4).
17. Takei R, Yamano Y, Kataoka K, Yokoyama T, Matsuda T, Kimura T, et al. Usefulness of new diagnostic criteria for chronic hypersensitivity pneumonitis established on the basis of a Delphi survey: A Japanese cohort study. *Respir Investig*. 2020;58(1):52-8.
18. Schuyler M, Cormier Y. The diagnosis of hypersensitivity pneumonitis. *Chest*. 1997;111(3):534-6.

19. Meyer KC, Raghu G, Baughman RP, Brown KK, Costabel U, du Bois RM, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;185(9):1004-14.

Figures

Figure 1

Case selection

Figure 2

A cubic spline demonstrating non-linear relationship between bronchoalveolar lavage lymphocytosis and predicted hazard ratio for all-cause mortality, with 95% confident interval (dash line), in patients with fibrotic hypersensitivity pneumonitis

Figure 3

Kaplan-Meier comparison of survival between f-HP with BAL lymphocytosis $\geq 30\%$ vs $< 30\%$ at presentation (Log rank = 0.034; BAL lymphocytosis $\geq 30\%$ median survival: 262 months, BAL lymphocytosis $< 30\%$ median survival: > 70 months)

Figure 4

Kaplan-Meier comparison of survival between fibrotic and non-fibrotic hypersensitivity pneumonitis (Log rank = <0.0001 ; f-HP median survival (bold): 77 months, non-fibrotic HP median survival (dashed): > 200 months)